The application of monoclonal antibodies (mAbs) and antibody drug conjugates as biologic drug therapies is an area of highly active research. Antibody characterization is an essential part of the biopharmaceutical development process. It is needed to differentiate among biologics/biosimilars, to help screen mAb drug candidates, to optimize production processes, and to satisfy regulatory requirements. Initially, the generation of monoclonal antibodies involved fusing cells from tissues and tumors to create hybridomas—a costly and often low-yield undertaking. Today, cell-line development and more efficient manufacturing techniques have emerged. Furthermore, a range of methods are used to determine the class and subclass of the antibody, including ELISA, radioimmunoassay, surface plasmon resonance, Western and dot blotting, mass spectrometry, and flow cytometry. In this webinar, the speakers will discuss how flow cytometry has advanced antibody characterization and how this method is used in their respective fields of research.
During the webinar, the speakers will:
- Discuss the importance of therapeutic antibodies, the challenges of their isolation, and the future of the field
- Offer general background on the importance of, and methods for, antibody characterization, with an emphasis on flow cytometry
- Outline the differences of traditional flow vs. advanced flow cytometry for antibody characterization
- Provide an overview of the spectrum of antibody characterization tools and highlight the benefits of advanced flow cytometry
- Answer your questions live during the broadcast.
This webinar will last for approximately 60 minutes.